Coherus BioSciences, Inc. (CHRS)
Stock Price:
$18.46 USD
-0.16 (-0.86%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $18.46 +0.00 (0.01%) Nov 30, 5:13 PM
Key Info
| Market Cap |
1.33B |
| Revenue (ttm) |
489.26M |
| Net Income (ttm) |
161.76M |
| Shares Out |
72.05M |
| EPS (ttm) |
2.05 |
| PE Ratio |
9.00 |
| Forward PE |
12.85 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$18.46 |
| Previous Close |
$18.62 |
| Change ($) |
-0.16 |
| Change (%) |
-0.86% |
| Day's Open |
18.53 |
| Day's Range |
18.16 - 18.77 |
| Day's Volume |
574,207 |
| 52-Week Range |
11.67 - 22.53 |
More Stats
| Market Cap |
1.33B |
| Enterprise Value |
1.24B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
72.05M |
| Float |
n/a |
| EPS (basic) |
2.28 |
| EPS (diluted) |
2.05 |
| FCF / Share |
1.85 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
11.11% |
| FCF Yield |
9.94% |
| Payout Ratio |
n/a |
| Shares Short |
15.76M |
| Short Ratio |
17.26 |
| Short % of Float |
n/a |
| Beta |
1.69 |
| PE Ratio |
9.00 |
| Forward PE |
12.85 |
| P/FCF Ratio |
10.06 |
| PS Ratio |
2.72 |
| PB Ratio |
5.09 |
| Revenue |
489.26M |
| Operating Income |
184.93M |
| Net Income |
161.76M |
| Free Cash Flow |
132.23M |
| Net Cash |
89.67M |
| Net Cash / Share |
1.24 |
| Gross Margin |
50.06% |
| Operating Margin |
37.80% |
| Profit Margin |
33.10% |
| FCF Margin |
27.03% |
| ROA |
20.45% |
| ROE |
103.78% |
| ROIC |
33.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (10)
| Buy |
8 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.90*
(61.97% upside)
Low
19.0
Current: $18.46
High
35.0
Target: 29.90
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 356 | - | 1.56 | 190 | 30.04 | 31.11 | 2.75 | 1.90 |
| Revenue Growth | - | - | -99.18% | 532.82% | -3.42% | 1030.72% | 44.87% | - |
| Gross Profit | 339 | - | 1.56 | 190 | 30.04 | 31.11 | 2.75 | 1.90 |
| Operating Income | 108 | -204 | -232 | -116 | -219 | -64.68 | -35.99 | -38.52 |
| Net Income | 89.83 | -209 | -238 | -127 | -223 | -87.13 | -53.64 | -33.02 |
| Shares Outstanding | 69.68 | 65.03 | 53.13 | 41.91 | 37.12 | 8.19 | 3.33 | 2.08 |
| Earnings Per Share | 1.23 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -16.10 | -15.85 |
| Operating Cash Flow | 28.36 | -159 | -200 | -253 | -108 | -23.93 | 15.42 | -18.25 |
| Capital Expenditures | -1.82 | -0.79 | -4.57 | -6.52 | -6.16 | -2.85 | -0.37 | -1.78 |
| Free Cash Flow | 26.53 | -160 | -205 | -259 | -114 | -26.78 | 15.05 | -20.03 |
| Cash & Equivalents | 178 | 72.41 | 127 | 125 | 158 | 152 | 39.71 | - |
| Total Debt | 189 | 103 | 102 | 100 | - | - | 4.20 | - |
| Net Cash / Debt | -10.97 | -30.69 | 25.36 | 24.75 | 158 | 152 | 35.51 | - |
| Assets | 409 | 99.47 | 163 | 178 | 212 | 187 | 47.45 | - |
| Liabilities | 304 | 138 | 132 | 159 | 219 | 120 | 89.83 | - |
| Book Value | 105 | -38.59 | 31.82 | 20.53 | -6.21 | 66.80 | -97.08 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Coherus BioSciences, Inc. |
| Country |
United States |
| Employees |
306 |
| CEO |
Denny M. Lanfear |
Stock Information
| Ticker Symbol |
CHRS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CHRS |
| IPO Date |
November 6, 2014 |
Description
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Company; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.